Incyte Announces Launch of the Incyte Ingenuity Award Program to Recognize Innovation Within the GVHD Community
February 19 2020 - 9:00AM
Business Wire
- Up to $100,000 to be awarded for an innovative solution
addressing an unmet need in the graft-versus-host disease (GVHD)
community
- Visit www.IncyteIngenuityAward.com to apply now!
Incyte (Nasdaq:INCY) is proud to announce the opening call for
submissions for its newly launched Incyte Ingenuity Award, an
annual program created to support people living with
graft-versus-host disease (GVHD), as well as their caregivers and
physicians, by encouraging innovative and novel solutions for the
challenges currently facing the GVHD community. Each year, the
Incyte Ingenuity Award is expected to fund, up to $100,000, one
innovative program, idea or initiative that fosters collaboration
within the GVHD community to address a specific unmet need.
This press release features multimedia. View
the full release here:
https://www.businesswire.com/news/home/20200219005221/en/
“At Incyte, we wanted to create a community-driven program
dedicated to improving the lives of patients with a serious
disease, such as GVHD, which can be difficult to treat and have a
devastating impact on the lives of patients,” said Barry Flannelly,
Pharm. D., Executive Vice President and General Manager, U.S.,
Incyte. “Through the Incyte Ingenuity Award, we hope to spark
creativity and innovation, which we expect to result in impactful
and actionable solutions for the GVHD community.”
Submissions are welcomed from non-profit 501(c)(3), patient,
policy and caregiver organizations, as well as healthcare providers
and mid-level/junior faculty from healthcare organizations.
Applications are due by April 30, 2020. All applications will be
reviewed and evaluated by an independent judging panel, consisting
of Gerry Cowden, Founder, Meredith Cowden Foundation; Shrina
Duggal, PharmD, BCOP, Clinical Pharmacy Specialist; and Navneet
Majhail, M.D., Director, Blood and Marrow Transplant Program,
Cleveland Clinic. The judging panel will review each application
and select the top three entries, who will then submit a more
detailed proposal of their initiative. The first award recipient of
Incyte Ingenuity Award will be announced in August of 2020.
“Through my practice, I see first-hand the struggles faced by
those impacted by GVHD. Everywhere they turn, patients experience a
limitation – whether it is through limited support, information
and/or treatment options. This award and its outputs are expected
to give the GVHD community hope for their future beyond this
horrible disease,” said Dr. Majhail. “I look forward to reviewing
the submitted applications and seeing the brilliant initiatives
that may come to fruition because of this generous award.”
To apply and learn more about the eligibility criteria, visit
www.IncyteIngenuityAward.com and submit an online application
including a summary of the proposed initiative.
About GVHD
GVHD is a condition that can occur after an allogeneic stem cell
transplant (the transfer of stem cells from a donor) where the
donated cells initiate an immune response and attack the transplant
recipient’s organs, leading to significant morbidity and mortality.
There are two major forms of GVHD, acute and chronic, that can
affect multiple organ systems including the skin, gastrointestinal
(digestive) tract, lung and liver.1
About Incyte
Incyte is a Wilmington, Delaware-based, global biopharmaceutical
company focused on finding solutions for serious unmet medical
needs through the discovery, development and commercialization of
proprietary therapeutics. For additional information on Incyte,
please visit Incyte.com and follow @Incyte.
References
- Leukemia & Lymphoma Society. "Graft-Versus-Host Disease
Facts." Available at:
http://www.lls.org/treatment/types-of-treatment/stem-cell-transplantation/graft-versus-host-disease.
Accessed January 2019.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20200219005221/en/
Media Jenifer Antonacci +1 302-498-7036
Jantonacci@incyte.com
Incyte (NASDAQ:INCY)
Historical Stock Chart
From Aug 2024 to Sep 2024
Incyte (NASDAQ:INCY)
Historical Stock Chart
From Sep 2023 to Sep 2024